The site offers advanced intermediate and API manufacturing from preclinical stages to commercial manufacturing. The 169-acre site is designed to manufacture a range of synthetic molecules, including small molecules, peptides, high potency APIs, and related conjugates.
It currently has 9 plants with a total reactor volume exceeding 1,000 m³ for small molecule products , and 12,000 L total reactor volume for peptide manufacturing. Among them, there is a dedicated API plant equipped with 13 production lines (each line includes dissolution reactor, crystallization reactor, filter dryer) and a hydrogenation plant with 7 reactors（200-8,000 L) , 10 flow hydrogenation lines, 22 post processing reactors.
